Current Hypertension Reports

, Volume 1, Issue 4, pp 320–327 | Cite as

Chronotherapeutics: Are there meaningful differences among antihypertensive drugs?

  • Luc Poirier
  • Jean Lefebvre
  • Yves Lacourciere
Article

Abstract

In the past decade, many publications have dealt with the possible relationship between biological rhythms and the incidence of cardiovascular events. A high proportion of treated hypertensive patients have cardiovascular complications, and chronotherapy, which permits the use of drugs that are maximally effective at different points in the circadian cycle, may be an interesting and valuable approach t decreasing morbidity and mortality in these patients. This article summarizes current knowledge on the new science of chronopharmacology, as demonstrated in several clinical studies that have used conventional agents administered at various points in the circadian cycle as well as new chronotherapeutic agents, such as controlled onset extended release (COER)-verapamil. In addition, emphasis is given to a rigorous evaluation of antihypertensive agents in terms of efficacy and duration of effect to obtain adequate and sustained lowering of blood pressure over the 24-hour period.

Keywords

Antihypertensive Agent Ambulatory Blood Pressure Ambulatory Blood Pressure Monitoring Nebivolol Isradipine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Lemmer B, Labrecque G: Chronopharmacology and chronotherapeutics: definitions and concepts. Chronobiol Int 1987, 4:319–329.PubMedGoogle Scholar
  2. 2.
    Levi F: Biological rhythms, chronotherapy and nitrates. Ann Cardiol Angeiol 1997, 46:426–430.Google Scholar
  3. 3.
    Smolensky MH: Chronobiology and chronotherapeutics: applications to cardiovascular medicine. Am J Hypertens 1996, 9:11S-21S. Addresses the current aspects of knowledge and research on chronobiology and chronotherapeutics. Will help the reader to learn the theoritical basis of chronobiology and to see the future applications of this new science in cardiovascular therapy.PubMedGoogle Scholar
  4. 4.
    Smolensky MH: Knowledge and attitudes of American physicians and public about medical chronobiology and chronotherapeutics: findings of two 1996 Gallup surveys. Chronobiol Int 1998, 15:377–394.PubMedCrossRefGoogle Scholar
  5. 5.
    Mulcahy D, Keegan J, Cunningham D, et al.: Circadian variation of total ischemic burden and its alteration with antianginal agents Lancet 1988, 2:755–759.PubMedCrossRefGoogle Scholar
  6. 6.
    Fox K, Mulcahy D, Keegan J, et al.: Circadian patterns of myocardial ischemia. Am Heart J 1989, 118:1084–1087.PubMedCrossRefGoogle Scholar
  7. 7.
    Argentino C, Toni D, Rasura M, et al.: Circadian variation in the frequency of ischemic stroke. Stroke 1990, 12:387–389.CrossRefGoogle Scholar
  8. 8.
    Marler JR, Price TR, Clark GL, et al.: Morning increase in onset of ischemic stroke. Stroke 1989, 20:473–476.PubMedGoogle Scholar
  9. 9.
    Willich SN, Levy D, Rocco MB, et al.: Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987, 60:801–806.PubMedCrossRefGoogle Scholar
  10. 10.
    Muller JE, Stone PH, Turi ZG, et al.: Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985, 313:1315–1322.PubMedCrossRefGoogle Scholar
  11. 11.
    Muller JE, Toffler GH, Stone PH: Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989, 79:733–743.PubMedGoogle Scholar
  12. 12.
    Staessen J, Bulpitt CJ, O’Brien E, et al.: The diurnal blood pressure profile: a population study. Am J Hypertens 1992, 5:386–392.PubMedGoogle Scholar
  13. 13.
    Punzi HA: Why ambulatory blood pressure monitoring? Am J Health Syst Pharm 1998, 55:S12-S16.PubMedGoogle Scholar
  14. 14.
    Waeber B, Rutschmann B, Nüssberger J, et al.: Evaluation of antihypertensive therapy: discrepancies between office and ambulatory recorded blood pressure. J Hypertens 1991, 9:S53-S56.Google Scholar
  15. 15.
    The Scientific Committee: Consensus document on noninvasive ambulatory blood pressure monitoring. J Hypertens 1990, 8:S135-S140.Google Scholar
  16. 16.
    Neutel J, Smith D, Ram C: Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 1993, 94:181–187.PubMedCrossRefGoogle Scholar
  17. 17.
    Verdecchia P, Porcellati C, Schillaci G: Ambulatory blood pressure: an independant predictor of prognosis in essential hypertension. Hypertension 1994, 24:793–801.PubMedGoogle Scholar
  18. 18.
    Perloff D, Sokolow M, Cowan R, et al.: Prognostic value of ambulatory blood pressure measurements: further analyses. J Hum Hypertens 1989, 7:S3-S10.Google Scholar
  19. 19.
    Perloff D, Sokolow M, Cowan R: The prognostic value of ambulatory blood pressure. JAMA 1983, 249:2792–2798.PubMedCrossRefGoogle Scholar
  20. 20.
    Mancia G, Zanchetti A, Agebiti-Rosei E, et al.: Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997, 95:1464–1470.PubMedGoogle Scholar
  21. 21.
    Timio M, Lalli S, Venanzi S: Renal damage and night-time blood pressure in uremic, treated hypertensive patients: a 3 years prospective study. Proceedings of the Sixth European Meeting on Hypertension: 4-7 June 1993, Milan. J Hypertens 1993, 11:S490.CrossRefGoogle Scholar
  22. 22.
    White WB, Mehrotra DV, Black HR, et al.: Effects of controlledonset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers). COER-Verapamil Study Group. Am J Cardiol 1997, 80:469–74.PubMedCrossRefGoogle Scholar
  23. 23.
    Carter BL: Optimizing delivery systems to tailor pharmacotherapy to cardiovascular circadian events. Am J Health Syst Pharm 1998, 55:S17-S23. Discusses the importance of a better blood pressure control, especially during early morning hours, and the relative inability of some conventional antihypertensive agents to do this optimally. Emphasizes the importance to tailor pharmacotherapy to cardiovascular circadian events, and described the design, pharmacokinetics and pharmacodynamics as well as the clinical experience obtained s far with the new chronotherapeutic formulation of verapamil COER.PubMedGoogle Scholar
  24. 24.
    Anwar YA, White WB: Chronotherapeutics for cardiovascular disease. Drugs 1998, 55:631–643. Describes the relationship between time in terms of circadian variation and disease using various examples. Makes the point of the timing of administration versus the effects of conventional (nonchronotherapeutic) formulations of antihypertensive agents. Presents the results of the different clinical studies done with the new chronotherapeutic formulation verapamil (Chronovera or Covera HS).PubMedCrossRefGoogle Scholar
  25. 25.
    Palatini P, Racioppa A, Raule A, et al.: Effect of timing of administration on the plasma ACE inhibitor activity and the antihypertensive effect of quinapril. Clin Pharmacol Ther 1992, 52:378–383.PubMedCrossRefGoogle Scholar
  26. 26.
    Greminger P, Suter PM, Holm D, et al.: Morning versus evening administration of nifedipine gastrointestinal therapeutic system in the management of essential hypertension. Clin Investig 1994, 72:864–869.PubMedCrossRefGoogle Scholar
  27. 27.
    Lemmer B: Differential effects of antihypertensive drugs on circadian rhythm in blood pressure from the chronobiological point of view. Blood Press Monit 1996, 1:161–169.PubMedGoogle Scholar
  28. 28.
    Fogari R, Malocco E, Tettamanti F, et al.: Evening versus morning isradipine sustained release in essential hypertension: a double-blind study with 24-hour ambulatory monitoring. Br J Clin Pharmacol 1993, 35:51–54.PubMedGoogle Scholar
  29. 29.
    Lemmer B, Sasse U, Witte K, et al.: Pharmacokinetics and cardiovascular effects of a new sustained-release formulation of diltiazem [abstract]. Arch Pharmacol 1994, 349S:R141.Google Scholar
  30. 30.
    Meilhac B, Mallion JM, Carre A, et al.: Étude de l’influence de l’horaire de la prise sur l’effet antihypertenseur et la tolérance de la nitrendipine chez des patients hypertendus essentiels légers à modérés. Therapie 1992, 47:205–210.PubMedGoogle Scholar
  31. 31.
    Umeda T, Naomi S, Iwaoka K, et al.: Timing of administration of am antihypertensive drug in the treatment of essential hypertension. Hypertension 1994, 23:1211–1214.Google Scholar
  32. 32.
    Palatini P, Mos L, Mormino P, et al.: Effect of evening versus morning benazepril on 24-hour blood pressure: a comparative study with continuous intraarterial monitoring. Int J Clin Pharmacol Ther 1993, 31:295–300.Google Scholar
  33. 33.
    Witte K, Weisser K, Neubeck M, et al.: Cardiovascular effects, pharmacokinetics, and converting enzyme inhibition o enalapril after morning versus evening administration. Clin Pharmacol Ther 1993, 54:177–186.PubMedCrossRefGoogle Scholar
  34. 34.
    Conte G, Rigon N, Perrone A: Application of chronotherapy to cardiovascular disease. Recenti Prog Med 1998, 89:465–469.PubMedGoogle Scholar
  35. 35.
    Kario K, Matsuo T, Kobayashi H, et al.: Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients: advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996, 27:130–135.PubMedGoogle Scholar
  36. 36.
    Burt VL, Whelton P, Roccella EJ, et al.: Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995, 25:305–313.PubMedGoogle Scholar
  37. 37.
    Chockalingam A, Fodor JG: Treatment of raised blood pressure in the population: the Canadian experience. Am J Hypertens 1998, 11:747–749.PubMedCrossRefGoogle Scholar
  38. 38.
    Mancia G, Cattaneo BM, Omboni S, et al.: Clinical benefits of a consistent reduction in blood pressure. J Hypertens Suppl 1998, 16:S35-S39. Emphasizes the importance of a consistent reduction in blood pressure in light of a reduction on morbidity and mortality. However, the authors suggest that we should use antihypertensive agents that confer 24-hour blood pressure control and therefore, possess a long duration of action. Presents the performance of several antihypertensive agents based on different end points (eg, trough:peak ratio, ambulatory blood presssure).PubMedGoogle Scholar
  39. 39.
    WHO/ISH Guidelines Sub-Committee. Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993, 11:905–918.CrossRefGoogle Scholar
  40. 40.
    Zannad F, Matzinger A, Larché J: Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996, 9:633–643.PubMedCrossRefGoogle Scholar
  41. 41.
    Lefebvre J, Poirier L, Archambault F, et al.: Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study. Can J Cardiol 1998, 14:682–688.PubMedGoogle Scholar
  42. 42.
    Lacourciere Y, Poirier L, Lefebvre J, et al.: Clinical efficacy of force titrated doses of diltiazem extended-release: a placebo-controlled study. Am J Hypertens 1995, 8:282–286.PubMedCrossRefGoogle Scholar
  43. 43.
    Lacourciere Y, Lefebvre J, Poirier L, et al.: Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination: a randomized, double-blind, placebo-controlled, factorial-design trial. Am J Hypertens 1994, 7:137–45.PubMedGoogle Scholar
  44. 44.
    Lacourciere Y, Poirier L, Dion D, et al.: Antihypertensive effect of isradipine administered once or twice daily on ambulatory blood pressure. Am J Cardiol 1990, 65:467–72.PubMedCrossRefGoogle Scholar
  45. 45.
    Black HR, Elliott WJ, Neaton JD, et al.: Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. Control Clin Trials 1998, 19:370–390. The description of the design, the methodoogy, and the end points of this important study are presented. The CONVINCE study is the first major trial to measure the impact of using chronotherapeutics in comparison with conventional antihypertensive agents on a multitude of cardiovascular end points.PubMedCrossRefGoogle Scholar
  46. 46.
    White WB: A chronotherapeutic approach to the management of hypertension. Am J Hypertens 1996, 9:29S-33S.PubMedGoogle Scholar
  47. 47.
    White WB, Black HR, Weber MA, et al.: Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. Am J Cardiol 1998, 81:424–431.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 1999

Authors and Affiliations

  • Luc Poirier
    • 1
  • Jean Lefebvre
    • 1
  • Yves Lacourciere
    • 1
  1. 1.Unité de recherche sur l’hypertensionSte-FoyCanada

Personalised recommendations